A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamic (PD) Effects of Posiphen in Subjects with Early Alzheimers Disease (AD) DISCOVER
Sponsor: |
Alzheimer's Disease Cooperative Study ADCS |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAR6583 |
U.S. Govt. ID: |
NCT02925650 |
Contact: |
Evelyn Dominguez: 212-305-2371 / edd5@cumc.columbia.edu |
This study is an early phase study of a medication for Alzheimer's Disease, with examination of cerebrospinal fluid.
This study is closed
Investigator
Lawrence Honig, MD, PhD
Are you between the ages of 55-85 (inclusive)? |
Yes |
No |
Do you have Early AD (including Mild Cognitive Impairment due to Alzheimers disease (MCI-AD) or mild Alzheimers disease? |
Yes |
No |